Civitelli Livia, Sandin Linnea, Nelson Erin, Khattak Sikander Iqbal, Brorsson Ann-Christin, Kågedal Katarina
From Experimental Pathology, Department of Clinical and Experimental Medicine and
From Experimental Pathology, Department of Clinical and Experimental Medicine and.
J Biol Chem. 2016 Apr 22;291(17):9233-43. doi: 10.1074/jbc.M115.696229. Epub 2016 Feb 23.
Aggregation of the amyloid-β peptide (Aβ) in the brain leads to the formation of extracellular amyloid plaques, which is one of the pathological hallmarks of Alzheimer disease (AD). It is a general hypothesis that soluble prefibrillar assemblies of the Aβ peptide, rather than mature amyloid fibrils, cause neuronal dysfunction and memory impairment in AD. Thus, reducing the level of these prefibrillar species by using molecules that can interfere with the Aβ fibrillation pathway may be a valid approach to reduce Aβ cytotoxicity. Luminescent-conjugated oligothiophenes (LCOs) have amyloid binding properties and spectral properties that differ when they bind to protein aggregates with different morphologies and can therefore be used to visualize protein aggregates. In this study, cell toxicity experiments and biophysical studies demonstrated that the LCO p-FTAA was able to reduce the pool of soluble toxic Aβ species in favor of the formation of larger insoluble nontoxic amyloid fibrils, there by counteracting Aβ-mediated cytotoxicity. Moreover, p-FTAA bound to early formed Aβ species and induced a rapid formation of β-sheet structures. These p-FTAA generated amyloid fibrils were less hydrophobic and more resistant to proteolysis by proteinase K. In summary, our data show that p-FTAA promoted the formation of insoluble and stable Aβ species that were nontoxic which indicates that p-FTAA might have therapeutic potential.
大脑中β淀粉样肽(Aβ)的聚集会导致细胞外淀粉样斑块的形成,这是阿尔茨海默病(AD)的病理特征之一。一个普遍的假说是,Aβ肽的可溶性前纤维聚集体而非成熟的淀粉样纤维,会导致AD中的神经元功能障碍和记忆损伤。因此,通过使用能够干扰Aβ纤维化途径的分子来降低这些前纤维聚集体的水平,可能是降低Aβ细胞毒性的一种有效方法。发光共轭低聚噻吩(LCOs)具有淀粉样蛋白结合特性,并且当它们与不同形态的蛋白质聚集体结合时,其光谱特性会有所不同,因此可用于可视化蛋白质聚集体。在本研究中,细胞毒性实验和生物物理研究表明,LCO p - FTAA能够减少可溶性有毒Aβ聚集体的数量,促进形成更大的不溶性无毒淀粉样纤维,从而抵消Aβ介导的细胞毒性。此外,p - FTAA与早期形成的Aβ聚集体结合,并诱导β折叠结构快速形成。这些由p - FTAA生成的淀粉样纤维疏水性较低,对蛋白酶K的蛋白水解作用更具抗性。总之,我们的数据表明,p - FTAA促进了无毒的不溶性稳定Aβ聚集体的形成,这表明p - FTAA可能具有治疗潜力。